Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–7 of 7 results
Advanced filters: Author: "Robert A. Hegele" Clear advanced filters

  • Raising high-density lipoprotein cholesterol (HDL-C) levels has attracted considerable interest as an approach for the treatment of cardiovascular disease. However, the failure of the HDL-raising investigational drug torcetrapib in clinical trials has led to significant doubts about the potential of this strategy. This article considers possible reasons for the failure of torcetrapib, and discusses alternative agents and strategies that might effectively, and safely, raise HDL-C.

    • Tisha Joy
    • Robert A. Hegele
    Reviews
    Nature Reviews Drug Discovery
    Volume: 7, P: 143-155

  • A single definition for the metabolic syndrome is not forthcoming since discussion of its forms and causes is continuing. Genetic causes and onset of the syndrome in relation to triggering genetic–environment interactions have been suggested. In this Review, the currently available knowledge about the most common purported genetic causes is drawn together.

    • Rebecca L Pollex
    • Robert A Hegele
    Reviews
    Nature Clinical Practice Cardiovascular Medicine
    Volume: 3, P: 482-489

  • Several known candidate gene variants are useful markers for diagnosing hyperlipoproteinemia. In this paper the authors evaluate the association of two commonAPOA5 single-nucleotide polymorphisms across the range of classic hyperlipoproteinemia phenotypes. Their data shows that a high proportion of patients with four classic hyperlipoproteinemia phenotypes are carriers of either the APOA5S19W or −1131T>C variant or both. The authors conclude that these two variants are robust genetic biomarkers of a range of clinical hyperlipoproteinemia phenotypes linked by hypertriglyceridemia.

    • Jian Wang
    • Matthew R Ban
    • Robert A Hegele
    Research
    Nature Clinical Practice Cardiovascular Medicine
    Volume: 5, P: 730-737

  • Niacin exerts several beneficial lipid-altering effects, including lowering the levels of atherogenic particles that contain apolipoprotein B and raising HDL cholesterol levels. This article reviews the utility of niacin including its mechanism of action, clinical trial data regarding cardiovascular outcomes, adverse effect profile and strategies to address these effects and improve compliance.

    • Julia C. Creider
    • Robert A. Hegele
    • Tisha R. Joy
    Reviews
    Nature Reviews Endocrinology
    Volume: 8, P: 517-528

  • HDL-cholesterol levels in plasma predict the risk of cardiovascular disease, but a direct causal role for HDL in cardiovascular disease remains controversial. In this Review, Rosenson et al. discuss the opportunities afforded by an integrated approach that combines human genetic studies with systems biology to understand the complex metabolism of HDL and its potential atheroprotective properties.

    • Robert S. Rosenson
    • H. Bryan Brewer Jr
    • Robert A. Hegele
    Reviews
    Nature Reviews Cardiology
    Volume: 15, P: 9-19

  • Lifestyle modification is recommended in all patients with dyslipidaemia to improve their lipid profile and reduce cardiovascular risk. Here, Hunter and Hegele discuss the mechanisms of action, safety and efficacy of a range of functional foods and dietary supplements with lipid-lowering properties.

    • Paola M. Hunter
    • Robert A. Hegele
    Reviews
    Nature Reviews Endocrinology
    Volume: 13, P: 278-288